File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Association between the liver fat score (LFS) and cardiovascular diseases in the national health and nutrition examination survey 1999–2016

TitleAssociation between the liver fat score (LFS) and cardiovascular diseases in the national health and nutrition examination survey 1999–2016
Authors
KeywordsCardiovascular disease prevention
Metabolic syndrome
Non-alcoholic fatty liver disease score
Liver fat score
Issue Date2021
PublisherTaylor & Francis. The Journal's web site is located at https://www.tandfonline.com/journals/iann20
Citation
Annals of Medicine, 2021, v. 53 n. 1, p. 1067-1075 How to Cite?
AbstractBackground: The liver fat score (LFS) has been proposed to be a simple non-invasive marker of non-alcoholic fatty liver disease (NAFLD), which is highly prevalent in the general population. We tested its association with cardiovascular diseases (CVDs) and prognosis. Methods: 17,244 adult participants from the National Health and Nutrition Examination Survey 1999–2016 were included. LFS is calculated from variables including serum aspartate transaminase/alanine transaminase (AST/ALT) ratio, fasting serum aspartate transaminase (AST) level, fasting serum insulin level, presence of metabolic syndrome and diabetes mellitus. In cross-sectional analysis, logistic regression was used to examine the association of the LFS with coronary heart disease (CHD), myocardial infarction (MI), congestive heart failure (CHF), stroke and angina pectoris. Mortality during follow-up was analysed using Cox proportional hazard regression. Results: LFS was associated with CHD (adjusted odds ratio [OR]: 1.09 per standard deviation [SD], 95% confidence interval [95% CI]: 1.03–1.15) (p = .003), CHF (1.11, 1.04–1.18) (p = .003) and angina pectoris (1.08, 1.02–1.13) (p = .005). LFS was not associated with MI or stroke, but was associated with increased all-cause and cardiovascular mortality with hazard ratios (HRs) of 1.10 (95% CI: 1.07–1.13) (p < .001) and 1.12 (95% CI: 1.06–1.17) (p < .001), respectively. Conclusions: NAFLD is usually asymptomatic, but this large study of a large general population shows that LFS is associated with CHD, CHF, angina pectoris, cardiovascular and all-cause mortality. Determining the LFS is worthwhile, as it identifies people with NAFLD, who may also be at increased cardiovascular risk.
Persistent Identifierhttp://hdl.handle.net/10722/304690
ISSN
2020 Impact Factor: 4.709
2020 SCImago Journal Rankings: 1.150
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLee, CO-
dc.contributor.authorLi, HL-
dc.contributor.authorTsoi, MF-
dc.contributor.authorCheung, CL-
dc.contributor.authorCheung, BMY-
dc.date.accessioned2021-10-05T02:33:45Z-
dc.date.available2021-10-05T02:33:45Z-
dc.date.issued2021-
dc.identifier.citationAnnals of Medicine, 2021, v. 53 n. 1, p. 1067-1075-
dc.identifier.issn0785-3890-
dc.identifier.urihttp://hdl.handle.net/10722/304690-
dc.description.abstractBackground: The liver fat score (LFS) has been proposed to be a simple non-invasive marker of non-alcoholic fatty liver disease (NAFLD), which is highly prevalent in the general population. We tested its association with cardiovascular diseases (CVDs) and prognosis. Methods: 17,244 adult participants from the National Health and Nutrition Examination Survey 1999–2016 were included. LFS is calculated from variables including serum aspartate transaminase/alanine transaminase (AST/ALT) ratio, fasting serum aspartate transaminase (AST) level, fasting serum insulin level, presence of metabolic syndrome and diabetes mellitus. In cross-sectional analysis, logistic regression was used to examine the association of the LFS with coronary heart disease (CHD), myocardial infarction (MI), congestive heart failure (CHF), stroke and angina pectoris. Mortality during follow-up was analysed using Cox proportional hazard regression. Results: LFS was associated with CHD (adjusted odds ratio [OR]: 1.09 per standard deviation [SD], 95% confidence interval [95% CI]: 1.03–1.15) (p = .003), CHF (1.11, 1.04–1.18) (p = .003) and angina pectoris (1.08, 1.02–1.13) (p = .005). LFS was not associated with MI or stroke, but was associated with increased all-cause and cardiovascular mortality with hazard ratios (HRs) of 1.10 (95% CI: 1.07–1.13) (p < .001) and 1.12 (95% CI: 1.06–1.17) (p < .001), respectively. Conclusions: NAFLD is usually asymptomatic, but this large study of a large general population shows that LFS is associated with CHD, CHF, angina pectoris, cardiovascular and all-cause mortality. Determining the LFS is worthwhile, as it identifies people with NAFLD, who may also be at increased cardiovascular risk.-
dc.languageeng-
dc.publisherTaylor & Francis. The Journal's web site is located at https://www.tandfonline.com/journals/iann20-
dc.relation.ispartofAnnals of Medicine-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectCardiovascular disease prevention-
dc.subjectMetabolic syndrome-
dc.subjectNon-alcoholic fatty liver disease score-
dc.subjectLiver fat score-
dc.titleAssociation between the liver fat score (LFS) and cardiovascular diseases in the national health and nutrition examination survey 1999–2016-
dc.typeArticle-
dc.identifier.emailCheung, CL: lung1212@hku.hk-
dc.identifier.emailCheung, BMY: mycheung@hkucc.hku.hk-
dc.identifier.authorityCheung, CL=rp01749-
dc.identifier.authorityCheung, BMY=rp01321-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1080/07853890.2021.1943514-
dc.identifier.pmid34184611-
dc.identifier.pmcidPMC8245099-
dc.identifier.scopuseid_2-s2.0-85109164627-
dc.identifier.hkuros326192-
dc.identifier.volume53-
dc.identifier.issue1-
dc.identifier.spage1067-
dc.identifier.epage1075-
dc.identifier.isiWOS:000667962000001-
dc.publisher.placeSweden-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats